AB0429 Clinical manifestations and their association with the immunological profile of primary sjögren’s syndrome
Authors: S. Fernandez Nacul, A. Secco, M. Oliver, M. Gauna, D. Puente Trigo, L. Santiago, A. Catalan Pellet, S. Velez, F. Zazzetti, J. Barreira, D. Duarte Noe, P. Pucci, C. Amitrano, C. Asnal, A. Nitsche, F. Cairo, M. Haye Salinas, L. Encinas, O. Rillo, S. Papasidero, M. Tamborenea, L. Raiti, J. Hofman, G. Salvatierra, E. Albiero
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> 1-Describe the frequency of the clinical manifestations. 2- Assess their association with the antibodies anti Ro/La, ANA, Rheumatoid Factor (RF) in patients with Primary Sjögren's Syndrome (pSS). <h3>Methods</h3> It was analyzed the information from the GESSAR's (Argentine Sjögren's Syndrome Group of Study) database of patients diagnosed with pSS according to 2002 American-European criteria. <h3>Results</h3> Out of 334 patients, 96% were women, with a median age of 57 (riq: 45-66), a median age at time of diagnosis of 52 (riq: 39-61) and a median age at onset of the symptoms of 47 (riq: 34-57), 95.78% presented xerophthalmia, 93.37% xerostomia, 32.18% parotid gland enlargement, 68.29% arthralgias, 29.58% arthritis, 8.22% purpura, 15.76% Raynaud's disease, 5.41% pulmonary parenchymal affection, 3.60% renal affection, 9.24% peripheral neuropathy, 16.46% anemia of chronic diseases, 13.13% leukopenia and 49.36% polyclonal hypergammaglobulinemia. Anti Ro/anti La + 242/322, ANA + 264/319, RF + 138/299. In univariate analysis anti Ro/La was significantly associated with age (OR 0.98 IC95% 0.96-0.99, p&lt;0.01), age at diagnosis (OR 0.97 IC95% 0.95-0.99, p&lt;0.01), polyclonal hypergammaglobulinemia (OR 4.17 IC95% 1.94-8.96, p&lt;0.01), anemia of chronic diseases (OR 2.53 IC95% 1.10-5.82, p=0.03), ANA (OR 10.93 IC95% 5.50-21.73, p&lt;0.01), RF (OR 2.96 IC95% 1.67-5.23, p&lt;0.01). ANA was associated with age at diagnosis (OR 0.98 IC95% 0.96-0.997, p=0.03), polyclonal hypergammaglobulinemia (OR 3.58 IC95% 1.46-8.76, p&lt;0.01), anti /La (OR 10.93 IC95% 5.50-21.73, p&lt;0.01), RF (OR 3.53. IC95% 1.77- 7.07, p&lt;0.01), and RF was associated with polyclonal hypergammaglobulinemia (OR 2.65 IC95% 1.55-4.54, p&lt;0.01), parotid gland enlargement (OR 1.82 IC95% 1.1-3.01, p=0.02), anemia of chronic diseases (OR 2.24 IC95% 1.17-2.28, p:0.02), Ro/La (OR 2.96 IC95% 1.67-5.23, p&lt;0.01), ANA (OR 3.53 IC95% 1.77- 7.07, p&lt;0.01). In the multivariate analysis, it was found significant and independent association between <b>anti Ro/La</b> and hypergammaglobulinemia (OR 3.37. IC 95% 1.50-7.55, p&lt;0.01), age at time of diagnosis (OR 0.96. IC 95% 0.94-0.99, p&lt;0.01) and ANA (OR 5.59 IC95% 2.25-13.88, p&lt;0.01); the <b>ANA</b> remained associated with anti Ro/La (OR 9.14 IC95% 4.44-18.85, p&lt;0.01) and with RF (OR 2.3 IC95% 1.05-5.04, p:0.04); whereas the <b>RF</b> was associated independently with hypergammaglobulinemia (OR 2.27 IC95% 1.30-3.96, p&lt;0.01) and ANA (OR 4.32 IC95% 1.55-11.99, p&lt;0.01). <h3>Conclusions</h3> Sicca symptoms followed by arthralgias were the most frequent clinical manifestations. Hypergammaglobulinemia was the only manifestation significantly and independently associated with seropositivity for anti Ro/anti La antibodies and RF. <h3>Disclosure of Interest</h3> None Declared